Substituted indazoles, compositions containing them, method of production and use

1. A compound of the formula (I):

wherein:

a) R1 is selected from the group consisting of hydrogen, halogen, alkyl, alkenyl, alkynyl, aryl, cycloalkyl, substituted alkyl, substituted alkenyl, substituted alkynyl, substituted aryl, substituted cycloalkyl, CN, O(R2), OC(O)(R2), OC(O)N(R2)(R3), OS(O 2 )(R2), N(R2)(R3), N═C(R2)(R3), N(R2)C(O)(R3), N(R2)C(O)O(R3), N(R4)C(O)N(R2)(R3), N(R4)C(S)N(R2)(R3), N(R2)S(O 2 )(R3), C(O)(R2), C(O)O(R2), C(O)N(R2)(R3), C(═N(R3))(R2), C(═N(OR3))(R2), S(R2), S(O)(R2), S(O 2 )(R2), and S(O 2 )N(R2)(R3), in which each R2, R3 and R4 is independently selected from the group consisting of hydrogen, alkyl, aryl, cycloalkyl, substituted alkyl, substituted aryl, substituted cycloalkyl, alkenyl and substituted alkenyl;

b) X is selected from the group consisting of S(O 2 )—HN; S(O 2 )—O; NH—S(O 2 ); and O—S(O 2 );

c) Z is selected from the group consisting of alkyl, aryl, cycloalkyl, substituted alkyl, substituted aryl, and substituted cycloalkyl; or

an enantiomer, stereoisomer, rotomer or a tautomer thereof, or a pharmaceutically acceptable salt, solvate or a derivative thereof,

with the proviso that the compound of formula (I) is not one of the following compound:

in which alkyl is n-propyl, and in which Ra and Rb are independently selected from the group consisting of NH 2 , NO 2 and Cl, or Ra and Rb form a ring —NH—CH═N—;

2. The compound as set forth in claim 1 , wherein X is S(O 2 )—NH or S(O 2 )—O.

3. The compound as set forth in claim 2 , wherein R1 is not hydrogen.

4. The compound as set forth in claim 3 , wherein Z is substituted aryl.

5. The compound as set forth in claim 4 , wherein Z is phenyl substituted with one to three substituents.

6. The compound as set forth in claim 5 , wherein Z is phenyl substituted with one or more substituents selected independently from the group consisting of: fluorine, chlorine and methylsulfonyl.

7. The compound as set forth in claim 1 , wherein R1 is selected from the group consisting of hydrogen, C 1 -C 6 alkyl, Cl, Br, I, CN, C(O)NH(R2), NHC(O)(R2), aryl, substituted aryl, alkenyl and substituted alkenyl.

8. The compound as set forth in claim 1 , which is chosen from the group consisting of:

N-(3-chloro-1H-indazol-5-yl)-2-methylsulfonylbenzenesulfonamide;

N-(3-chloro-1H-indazol-5-yl)-3,4-dichlorobenzenesulfonamide;

N-(3-chloro-1H-indazol-5-yl)-3-fluorobenzenesulfonamide;

N-(3-cyano-1H-indazol-5-yl)-3-fluorobenzenesulfonamide;

N-(3-cyano-1H-indazol-5-yl)-2methylsulfonylbenzenesulfonamide;

3-fluoro-N-(3-phenyl-1H-indazol-5-yl)benzenesulfonamide;

2-methylsulfonyl-N-(3-phenyl-1H-indazol-5-yl)benzenesulfonamide;

3,4-dichloro-N-(3-phenyl-1H-indazol-5-yl)benzenesulfonamide;

3-fluoro-N-(3-methyl-1H-indazol-5-yl)benzenesulfonamide;

2-methylsulfonyl-N-(3-methyl-1H-indazol-5-yl)benzenesulfonamide;

N-(3-fluorophenyl)-(1H-indazol-5-yl)sulfonamide;

3-fluoro-N-(3-iodo-1H-indazol-5-yl)benzenesulfonamide;

2-methysulfonyl-N-(1H-indazol-5-yl)benzenesulfonamide:

3,4-dichloro-N-(1H-indazol-5-yl)benzenesulfonamide;

3-fluoro-N-(1H-indazol-5-yl)benzenesulfonamide;

3-fluoro-N-(3-hydroxy-1H-indazol-5-yl)benzenesulfonamide;

1H-indazol-5-yl 3-fluorobenzenesulfonate;

N-phenyl-5-(2-methylsulfonylbenzenesulfonamino)-1H-indazole-3-carboxamide;

N-methyl-5-(3-fluorobenzenesulfonylamino)-1H-indazole-3-carboxamide;

5-(2-methylsulfonylbenzenesulfonylamino)-1H-indazole-3-carboxamide;

5-(3-fluorobenzenesulfonylamino)-1H-indazole-3-carboxamide;

N-phenyl-5-(3-fluorobenzenesulfonylamino)-1H-indazole-3-carboxamide; and

N-[5-(3-fluorobenzenesulfonylamino)-1H-indazol-3-yl]-benzamide.

9. A compound of the formula (IA):

wherein:

d) R1 is selected from the group consisting of hydrogen, halogen, alkyl alkenyl, alkynyl, aryl, cycloalkyl, substituted alkyl, substituted alkenyl, substituted alkynyl, substituted aryl, substituted cycloalkyl, CN, O(R2), OC(O)(R2), OC(O)N(R2)(R3), OS(O 2 )(R2), N(R2)(R3), N═C(R2)(R3), N(R2)C(O)(R3), N(R2)C(O)O(R3), N(R4)C(O)N(R2)(R3), N(R4)C(S)N(R2)(R3), N(R2)S(O 2 )(R3), C(O)(R2), C(O)O(R2), C(O)N(R2)(R3), C(═N(R3))(R2), C(═N(OR3))(R2), S(R2), S(O)(R2), S(O 2 )(R2) and S(O 2 )N(R2)(R3), in which each R2, R3 and R4 is independently selected from the group consisting of hydrogen, alkyl, uryl, cycloalkyl, substituted alkyl, substituted aryl, substituted cycloalkyl, alkenyl and substituted alkenyl;

e) X is selected from the group consisting of S(O 2 )—NH; S(O 2 )—NH; S(O 2 )—O; NH—S(O 2 ); and O—S(O 2 );

f) Z is selected from the group consisting of alkyl, alkenyl, aryl, cycloalkyl, substituted alkyl, substituted alkenyl, substituted aryl, and substituted cycloalkyl;

g) R is chosen from hydrogen or C1-C3 alkyl; or

an enantiomer, stereoisomer, rotomer or a tautomer thereof or a pharmaceutically acceptable salt, solvate or a derivative thereof,

with the proviso that the compound of formula (I) is not one of the following compound:

1)

wherein

(i) Aryl is 3-fluorophenyl and Subst is chosen from methyl, 2,2,2-trifluoroethyl, 4-methylphenyl,

(ii) Aryl is 4-fluorophenyl and Subst is phenyl,

(iii) Aryl is 4-trifluoromethylphenyl and Subst is N,N-dimethylamino,

(iv) Aryl is 3,4-methylenedioxyphenyl and Subst is 1-methylethyl,

(v) Aryl in phenyl and Subst is methyl, and

(vi) Aryl is 2-naphthyl and Subst is methyl;

2)

wherein

Subst is chosen from 3,4,5-trimethoxyphenyl, 2,3,4,5,6-pentafluorophenyl, methyl, and

 in which Ra and Rb are independently selected from the group consisting of NH 2 , NO 2 and Cl, or Ra and Rb taken together with the carbon atoms to which they are attached from a ring —NH—CH═N; and

3) when R1 is aryl or substituted aryl R is hydrogen.

10. The compound as set forth in claim 9 , wherein Z-X is chosen from Z-S(O 2 )—NH or Z-S(O 2 )—O.

11. The compound as set forth in claim 10 , wherein R is hydrogen.

12. The compound as set forth in claim 11 , wherein Z is chosen from 2-methylsulfonylphenyl, 3-fluorophenyl or 3,5-difluorophenyl.

13. The compound as set forth in claim 12 , wherein R1 selected from the group consisting of NH 2 , NHCOPh, NHCOMe, CONH 2 , CONHPh, phenyl, 3-cyanophenyl, 3-CO 2 MePh, 3-(Me 3 SiC≡C—)Ph, 3-nitrophenyl, 3-aminophenyl, 3-methylphenyl, 3-chlorophenyl, 3-fluorophenyl, 3-bromophenyl, 4-carboxyphenyl, 4-methoxyphenyl, 4-aminophenyl, and 4-hydroxyphenyl, 4-dimethylaminophenyl.

14. The compound as set forth in claim 9 , wherein Z is chosen from 2-methylsulfonylphenyl, 3-fluorophenyl, 2-trifluoromethoxyphenyl or phenyl.

15. The compound as set forth in claim 9 , wherein R1 is selected from the group consisting of 4-carboxyphenyl, 4-hydroxyphenyl, 4-demethylaminophenyl, styryl, 4-fluorophenylethylen-2-yl and 4-chlorophenylurethane-2-yl.

16. The compound as set forth in claim 9 , which is chosen from the group consisting of:

N-(1H-indazol-5-yl)benzenesulfonamide;

3,4-dichloro-N-(3-methyl-1H-indazol-5-yl)benzenesulfonamide;

N-(3-amino-1H-indazol-5-yl)-3-fluorobenzenesulfonamide;

3-fluoro-N-(3-methylsulfonylamino-1H-indazol-5-yl)benzenesulfonamide;

N-[5-(3-fluorobenzenesulfonylamino)-1H-indazol-3-yl)acetamide;

N-cyclohexyl-5-(2-methylsulfonylbenzenesulfonylamino)-1H-indazole-3-carboxamide;

N-[3-(4-chlorophenyl)-1H-indazol-5-yl]-2-methylsulfonylbenzenesulfonamide;

N-[3-(4-methoxyphenyl)-1H-indazol-5-yl]benzenesulfonamide;

N-[3-(4-methoxyphenyl)-1H-indazol-5-yl]-2-methylsulfonylbenzenesulfonamide;

N-[3-(4-fluorophenyl)-1H-indazol-5-yl]-2-methylsulfonylbenzenesulfonamide;

N-[3-(4-hydroxyphenyl)-1H-indazol-5-yl]benzenesulfonamide;

N-[3-(4-hydroxyphenyl)-1H-indazol-5-yl]-2-methylsulfonylbenzenesulfonamide;

N-(3-benzylamino-1H-indazol-5-yl)-2-methylsulfonylbenzenesulfonamide;

N-(3-methylamino-1H-indazol-5-yl)-2-methylsulfonylbenzenesulfonamide;

N-(3-bromo-1H-indazol-5-yl)-2-methylsulfonylbenzenesulfonamide;

N-(3-amino-1H-indazol-5-yl)-2-methylsulfonylbenzenesulfonamide;

N-(3-amino-1H-indazol-5-yl)-2,6-difluorobenzenesulfonamide;

N-(3-amino-1H-indazol-5-yl)-2,6-dichlorobenzenesulfonamide;

N-(3-amino-1H-indazol-5-yl)-3,5-difluorobenzenesulfonamide;

N-[5-(2-methylsulfonylbenzenesulfonylamino)-1H-indazol-3-yl)acetamide;

N-[5-(3,5-difluorobenzenesulfonylamino)-1H-indazol-3-yl)acetamide;

N-[5-(2-methylsulfonylbenzenesulfonylamino)-1H-indazol-3-benzamide;

N-[5-(3,5-difluorobenzenesulfonylamino)-1H-indazol-3-y1)benzamide;

N-{2-[5-(3-fluorobenzenesulfonylamino)-1H-indazol-3-yl]phenyl}acetamide;

N-{2-(5-(2methylsulfonylbenzenesulfonylamino)-1H-indazol-3-yl]phenyl}-acetamide;

N-[3-(2-aminophenyl)-1H-indazol-5-yl]-2-methylsulfonylbenzenesulfonamide;

N-[3-(3-aminophenyl)-1H-indazol-5-yl]-2-methylsulfonylbenzenesulfonamide;

N-[3-(4-dimethylaminophenyl)-1H-indazol-5-yl]-2-methylsulfonylbenzenesulfonamide;

N-[3-(4-nitrophenyl)-1H-indazol-5-yl]-2-methylsulfonylbenzenesulfonamide;

methyl 4-[5-(2-methylsulfonylbenzenesulfonamino)-1H-indazol-3-yl]benzoate;

4-[5-(2-methylsulfonylbenzenesulfonamino)-1H-indazol-3]benzoic acid;

N-[3-(4-aminophenyl)-1H-indazol-5-yl]-2-methylsulfonylbenzenesulfonamide;

N-[3-(3-cyanophenyl)-1H-indazol-5-yl]-2-methylsulfonylbenzenesulfonamide;

2-methylsulfonyl-N-(3-naphthalen-1-yl-1H-indazol-5-yl)benzenesulfonamide;

2-methylsulfonyl-N-(3-naphthalen-2-yl-1H-indazol-5-yl)benzenesulfonamide;

N-{3-[(E)-2-(4-fluorophenyl)vinyl]-1H-indazol-5-yl}-2-methylsulfonylbenzenesulfonamide;

N-{3-[2-(4-fluorophenyl)ethyl]-1H-indazol-5-yl}-2-methylsulfonylbenzenesulfonamide;

N-{3-[2-(4-chlorophenyl)vinyl]-1H-indazol-5-yl}-2-methylsulfonylbenzenesulfonamide;

N-{3-[2-(4-chlorophenyl)ethyl]-1H-indazol-5-yl}-2-methylsulfonylbenzenesulfonamide

2-methylsulfonyl-N-[3-((E)-styryl)-1H-indazol-5-yl]benzenesulfonamide;

methyl (E)-3-[5(2-methylsulfonylbenzenesulfonylamino)-1H-indazol-3-yl]-acrylate;

(E)-3-[5(2-methylsulfonylbenzenesulfonylamino)-1H-indazol-3-yl]acrylic acid;

2-methylsulfonyl-N-(3-phenylamino-1H-indazol-5-yl)benzenesulfonamide;

2-methylsulfonyl-N-(3-phenylsulfonyl-1H-indazol-5-yl)benzenesulfonamide;

2-methylsulfonyl-N-(3-phenylethynyl-1H-indazol-5-yl)benzenesulfonamide;

2-methylsulfonyl-N-(3-phenylethyl-1H-indazol-5-yl)benzenesulfonamide;

2-methylsulfonyl-N-[3-(3-trimethylsilanylethynylphenyl)-1H-indazol-5-yl]benzenesulfonamide;

5-fluoro-2-methylsulfonyl-N-(3-phenyl-1H-indazol-5-yl)benzenesulfonamide;

4-amino-N-(3phenyl-1H-indazol-5-yl)benzenesulfonamide;

N-[4-(3-phenyl-1H-indazol-5-ylsulfamoyl)phenyl]acetamide;

3-nitro-N-(3-phenyl-1H-indazol-5-yl)benzenesulfonamide;

3-amino-N-(3-phenyl-1H-indazol-5-yl)benzenesulfonamide;

N-(3-phenyl-1H-indazol-5-yl)cyclohexanesulfonamide;

N-[3-(3,5-bis-trifluoromethylphenyl)-1H-indazol-5-yl]-2-methylsulfonylbenzenesulfonamide;

N-[3-(3,5-difluorophenyl)-1H-indazol-5-yl]-2-methylsulfonylbenzenesulfonamide;

2-methylsulfonyl-N-[3-(2methylsulfanylphenyl)-1H-indazol-5-yl]benzenesulfonamide;

2-methylsulfonyl-N-(3-o-tolyl-1H-indazol-5-yl)benzenesulfonamide;

N-(3-phenyl-1H-indazol-5-yl)naphthalene-1-sulfonamide;

5-dimethylamino-N-(3-phenyl-1H-indazol-5-yl)naphthalene-1-sulfonamide;

N-(3-phenyl-1H-indazol-5-yl)naphthalen-2-sulfonamide;

N-(3-phenyl-1H-indazol-5-yl)-2-trifluoromethylbenzenesulfonamide;

N-(3-phenyl-1H-indazol-5-yl)benzenesulfonamide;

2-nitro-N-(3-phenyl-1H-indazol-5-yl)benzenesulfonamide;

2,4,6-triisopropyl-N-(3-phenyl-1H-indazol-5yl)benzenesulfonamide;

2,4,6-trimethyl-N-(3-phenyl-1H-indazol-5)benzenesulfonamide;

4-bromo-N-(3-phenyl-1H-indazol-5-yl)benzenesulfonamide;

4-fluoro-N-(3-phenyl-1H-indazol-5-yl)benzenesulfonamide;

N-[4-(3-phenyl-1H-indazol-5-ylsulfamoyl)phenyl]acetamide;

4-nitro-N-(3phenyl-1H-indazol-5-yl)benzenesulfonamide;

4-methoxy-N-(3phenyl-1H-indazol-5-yl)benzenesulfonamide;

4-tert-butyl-N-(3phenyl-1H-indazol-5-yl)benzenesulfonamide;

4-methyl-N-(3phenyl-1H-indazol-5-yl)benzenesulfonamide;

1-methyl-N-(3phenyl-1H-indazol-5-yl)ethanesulfonamide;

N-(3phenyl-1H-indazol-5-yl)methanesulfonamide;

1-phenyl-N-(3phenyl-1H-indazol-5-yl)methanesulfonamide;

(E)-2-phenyl-N-(3phenyl-1H-indazol-5-yl)ethylenesulfonamide;

N-(3phenyl-1H-indazol-5-yl)ethanesulfonamide;

N-(3phenyl-1H-indazol-5-yl)propanesulfonamide;

N-(3phenyl-1H-indazol-5-yl)butanesulfonamide;

3-trifluoromethyl-N-(3phenyl-1H-indazol-5-yl)benzenesulfonamide;

2,5-dimethoxy-N-(3phenyl-1H-indazol-5-yl)benzenesulfonamide;

2-methyl-N-(3phenyl-1H-indazol-5-yl)benzenesulfonamide;

3-(3phenyl-1H-indazol-5-ylsulfamoyl)benzoic acid;

2-fluoro-N-(3phenyl-1H-indazol-5-yl)benzenesulfonamide;

3-chloro-N-(3phenyl-1H-indazol-5-yl)benzenesulfonamide;

3,5-dichloro-N-(3phenyl-1H-indazol-5-yl)benzenesulfonamide;

3-methyl-N-(3phenyl-1H-indazol-5-yl)benzenesulfonamide;

2-bromo-N-(3phenyl-1H-indazol-5-yl)benzenesulfonamide;

3-bromo-N-(3phenyl-1H-indazol-5-yl)benzenesulfonamide;

N-(3-phenyl-1H-indazol-5-yl)-2-trifluoromethoxybenzenesulfonamide;

4-cyano-N-(3phenyl-1H-indazol-5-yl)benzenesulfonamide;

2-cyano-N-(3phenyl-1H-indazol-5-yl)benzenesulfonamide;

4-butoxy-N-(3phenyl-1H-indazol-5-yl)benzenesulfonamide;

N-[2-chloro-4-(3-phenyl-1H-indazol-5-ylsufamoyl)phenyl]acetamide;

5-dibutylamino-N-(3-phenyl-1H-indazol-5-yl)naphthalene-1-sulfonamide;

C-(7,7-dimethyl-2-oxobicyclo[2,2.1]hept-1-yl)-N-(3-phenyl-1H-indazol-5-yl)methanesulfonamide;

C-(2-nitrophenyl)-N-(3phenyl-1H-indazol-5-yl)methanesulfonamide;

3,4-difluoro-N-(3phenyl-1H-indazol-5-yl)benzenesulfonamide;

3-cyano-N-(3phenyl-1H-indazol-5-yl)benzenesulfonamide;

4-methanesulfonyl-N-(3phenyl-1H-indazol-5-yl)benzenesulfonamide;

3-methoxy-N-(3phenyl-1H-indazol-5-yl)benzenesulfonamide;

N-(3phenyl-1H-indazol-5-yl)diphenyl-3-sulfonamide;

3,5-difluoro-N-(3phenyl-1H-indazol-5-yl)benzenesulfonamide;

2-amino-N-4,6-dichloro-N-(3phenyl-1H-indazol-5-yl)benzenesulfonamide;

4-trifluoromethoxy-N-(3phenyl-1H-indazol-5-yl)benzenesulfonamide;

N-[3-(4-bromophenyl)-1H-indazol-5-yl]-2-methanesulfonyl-benzenesulfonaminde;

2-methanesulfonyl-N-[3-(3-nitrophenyl)-1H-indazol-5-yl]benzenesulfonamide;

N-[3-(2,4-dichlorophenyl)-1H-indazol-5-yl]-2-methanesulfonyl-benzenesulfonamide;

2-methanesulfonyl-N-(3-p-tolyl-1H-indazol-5-yl)benzenesulfonamide;

2-methanesulfonyl-N-(3-m-tolyl-1H-indazol-5-yl)benzenesulfonamide;

N-{3-[5-(2-methanesulfonylbenzenesulfonylamino)-1H-indazol-3-yl]phenyl}-5-dimethylaminonaphthalene-1-sulfonamide;

N-[3-(3-chloro-4-fluorophenyl)-1H-indazol-5-yl]-2-methanesulfonyl-benzenesulfonamide;

N-[3-(3,5-dichlorophenyl)-1H-indazol-5-yl]-2-methanesulfonyl-benzenesulfonamide;

N-(3-biphenyl-4-yl-1H-indazol-5-yl)-2-methanesulfonylbenzenesulfonamide;

2-methanesulfonyl-N-[3-(4-phenoxy-phenyl)-1H-indazol-5-yl]-benzenesulfonamide;

2-methanesulfonyl-N-[3-(4-methylsulfanylphenyl)-1H-indazol-5-yl]-benzenesulfonamide;

N-(3-biphenyl-2-yl-1H-indazol-5-yl)-2-methanesulfonylbenzenesulfonamide;

N-[3-(3-trifluoromethylphenyl)-1H-indazol-5-yl]-2-methanesulfonyl-benzenesulfonamide;

N-[3-(4-trifluoromethylphenyl)-1H-indazol-5-yl]-2-methanesulfonyl-benzenesulfonamide;

N-[3-(3-chlorophenyl)-1H-indazol-5-yl]-2-methanesulfonyl-benzenesulfonamide;

2-methanesulfonyl-N-[3-(3-methoxyphenyl)-1H-indazol-5-yl]-benzenesulfonamide;

2-methanesulfonyl-N-[3-(3,5-dimethyphenyl)-1H-indazol-5-yl]-benzenesulfonamide;

N-[3-(3-fluorophenyl)-1H-indazol-5-yl]-2-methanesulfonyl-benzenesulfonamide;

2-methanesulfonyl-N-[3-(2-methoxyphenyl)-1H-indazol-5-yl]-benzenesulfonamide;

N-[3-(3-bromophenyl)-1H-indazol-5-yl]-2-methanesulfonyl-benzenesulfonamide;

2-methanesulfonyl-N-[3-(4-vinylphenyl)-1H-indazol-5-yl]benzenesulfonamide;

N-[3-(3-ethoxyphenyl)-1H-indazol-5-yl]-2-methanesulfonyl-benzenesulfonamide;

N-[3-(2-chlorophenyl)-1H-indazol-5-yl]-2-methanesulfonyl-benzenesulfonamide;

N-[3-(2-fluorophenyl)-1H-indazol-5-yl]-2-methanesulfonyl-benzenesulfonamide;

N-[3(2-ethoxyphenyl)-1H-indazol-5-yl]-2-methanesulfonyl-benzenesulfonamide;

N-[3-(4-ethoxyphenyl)-1H-indazol-5-yl]-2-methanesulfonyl-benzenesulfonamide;

N-[3-(4-hydroxymethylphenyl)-1H-indazol-5-yl]-2-methanesulfonyl-benzenesulfonamide;

N-[3(3,4-difluorophenyl)-1H-indazol-5-yl]-2-methanesulfonyl-benzenesulfonamide;

N-[3-(4-ethylphenyl)-1H-indazol-5-yl]-2-methanesulfonyl-benzenesulfonamide;

N-[3-(4-benzyloxy-3-fluorophenyl)-1H-indazol-5-yl]-2-methanesulfonyl-benzenesulfonamide;

2-methanesulfonyl-N-[3-(3,4-dimethyphenyl)-1H-indazol-5-yl]-benzenesulfonamide;

N-[3-(benzo[1,3]dioxol-5-yl)-1H-indazol-5-yl]-2-methanesulfonyl-benzenesulfonamide;

N-[3-(tert-butylphenyl)-1H-indazol-5-yl]-2-methanesulfonyl-benzenesulfonamide;

2-methanesulfonyl-N-[3-(2,4-dimethoxyphenyl)-1H-indazol-5-yl]-benzenesulfonamide;

2-methanesulfonyl-N-[3-(2,4-dimethoxyphenyl)-1H-indazol-5-yl]-benzenesulfonamide;

N-[3-(3-hydroxyphenyl)-1H-indazol-5-yl]-2-methanesulfonyl-benzenesulfonamide;

N-[3-(4-isopropylphenyl)-1H-indazol-5-yl]-2-methanesulfonyl-benzenesulfonamide;

N-[3-(4-hydroxyphenyl)-1H-indazol-5-yl]-2-methanesulfonyl-benzenesulfonamide;

N-[3-(3-isopropylphenyl)-1H-indazol-5-yl]-2-methanesulfonyl-benzenesulfonamide;

N-[3-(3-amino-4-methylphenyl)-1H-indazol-5-yl]-2-methanesulfonyl-benzenesulfonamide;

N-[3-(3,4-dichlorophenyl)-1H-indazol-5-yl]-2-methanesulfonyl-benzenesulfonamide;

N-[3-(4-trifluoromethoxyphenyl)-1H-indazol-5-yl]-2-methanesulfonyl-benzenesulfonamide;

N-[3-(4-acetylphenyl)-1H-indazol-5-yl]-2-methanesulfonyl-benzenesulfonamide;

N-[3-(2,3-dichlorophenyl)-1H-indazol-5-yl]-2-methanesulfonyl-benzenesulfonamide;

N-[3-(4-benzyloxyphenyl)-1H-indazol-5-yl]-2-methanesulfonyl-benzenesulfonamide;

N-[3-(2-fluorobiphenyl-4-yl)-1H-indazol-5-yl]-2-methanesulfonyl-benzenesulfonamide;

N-[3-(3,5-dibromophenyl)-1H-indazol-5-yl]-2-methanesulfonyl-benzenesulfonamide;

N-[3-(4-bromo-2-fluorophenyl)-1H-indazol-5-yl]-2-methanesulfonylbenzenesulfonamide;

N-[3-(4-ethylsulfanylphenyl)-1H-indazol-5-yl]-2-methanesulfonylbenzenesulfonamide;

2-methanesulfonyl-N-[3-(2,3,4-trimethoxyphenyl)-1H-indazol-5-yl]-benzenesulfonamide;

N-[3-(5-chloro-2-methoxyphenyl)-1H-indazol-5-yl]-2-methanesulfonylbenzenesulfonamide;

N-[3-(4-cyanophenyl)-1H-indazol-5-yl]-2-methanesulfonylbenzenesulfonamide;

N-[3-(2,4-difluorophenyl)-1H-indazol-5-yl]-2-methanesulfonylbenzenesulfonamide;

N-[3-(4-iodophenyl)-1H-indazol-5-yl]-2-methanesulfonylbenzenesulfonamide;

N-[3-(3-trifluoromethoxyphenyl)-1H-indazol-5-yl]-2-methanesulfonylbenzenesulfonamide;

2-methanesulfonyl-N-[3-(3-methanesulfonylphenyl)-1H-indazol-5-yl]-benzenesulfonamide;

N-[3-(2,3-difluorophenyl)-1H-indazol-5-yl]-2-methanesulfonylbenzenesulfonamide;

N-[3-(4-fluoro-3-methylphenyl)-1H-indazol-5-yl]-2-methanesulfonylbenzenesulfonamide;

N-[3-(3-benzyloxyphenyl)-1H-indazol-5-yl]-2-methanesulfonyl-benzenesulfonamide;

N-[3-(3-fluoro-4-methylphenyl)-1H-indazol-5-yl]-2-methanesulfonyl-benzenesulfonamide; and

N-[3-(2,5-dichlorophenyl)-1H-indazol-5-yl]-2-methanesulfonyl-benzenesulfonamide.

17. A pharmaceutical composition comprising one or more compounds as set forth in claim 1 , in combination with a pharmaceutically acceptable excipient.

18. A pharmaceutical composition comprising one or more compounds as set forth in claim 9 , in combination with a pharmaceutically acceptable excipient.

19. A method of treating a cancer selected from the group consisting of prostate cancer, breast cancer, thyroid cancer, colon cancer, melanoma, brain cancer and lung cancer, said cancer is associated with a reaction catalyzed by a kinase comprising administering to a patient in need of said treatment a therapeutically effective amount of a compound of formula (I), as an agent for inhibiting said reaction catalyzed by said kinase;

wherein:

h) R1 is selected from the group consisting of hydrogen, halogen, alkyl, alkenyl, alkynyl, aryl, cycloalkyl, substituted alkyl, substituted alkenyl, substituted alkynyl, substituted aryl, substituted cycloalkyl, CN, O(R2), OC(O)(R2), OC(O)N(R2)(R3), OS(O 2 )(R2), N(R2)(R3), N═C(R2)(R3), N(R2)C(O)(R3), N(R2)C(O)O(R3), N(R4)C(O)N(R2)(R3), N(R4)C(S)N(R2)(R3), N(R2)S(O 2 )(R3), C(O)(R2), C(O)O(R2), C(O)N(R2)(R3), C(═N(R3))(R2), C(═N(OR3))(R2), S(R2), S(O)(R2), S(O 2 )(R2) and S(O 2 )N(R2)(R3), in which each R2, R3 and R4 is independently selected from the group consisting of hydrogen, alkyl, aryl, cycloalkyl, substituted alkyl, substituted aryl, substituted cycloalkyl, alkenyl and substituted alkenyl;

i) X is selected from the group consisting of S(O 2 )—NH; S(O 2 )—O; NH—S(O 2 ); and O—S(O 2 );

j) Z is selected from the group consisting of alkyl, aryl, cycloalkyl, substituted alkyl, substituted aryl, and substituted cycloalkyl; or

an enantiomer, stereoisomer, rotomer or a tautomer thereof, or a pharmaceutically acceptable salt, solvate or a derivative thereof.

20. The method as set forth in claim 19 , wherein the kinase is FAK.

21. The method as set forth in claim 19 , wherein the kinase is Aurora2.

22. The method as set forth in claim 19 , wherein the kinase is KDR.

23. The method as set forth in claim 19 , wherein the kinase is selected from the group consisting of Src, Tie2, IGF1R, CDK2 and CDK4.

24. The method as set forth in claim 23 , wherein the kinase is selected from the group consisting of Src and Tie2.

25. The method as set forth in claim 19 , wherein the cancer is breast cancer.

26. A method of treating a cancer selected from the group consisting of prostate cancer, breast cancer, thyroid cancer, colon cancer, melanoma, brain cancer and lung cancer, said cancer is associated with a reaction catalyzed by a kinase comprising administering to a patient in need of said treatment a therapeutically effective amount of a compound of formula (IA), as an agent for inhibiting said reaction catalyzed by said kinase:

wherein:

k) R1 selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, aryl, cycloalkyl, substituted alkyl, substituted alkenyl, substituted alkynyl, substituted aryl, substituted cycloalkyl, CN, O(R2), OC(O)(R2), OC(O)N(R2)(R3), OS(O 2 )(R2), N(R2)(R3), N═C(R2)(R3), N(R2)C(O)(R3), N(R2)C(O)O(R3), N(R4)C(O)N(R2)(R3), N(R4)C(S)N(R2)(R3), N(R2)S(O 2 )(R3), C(O)(R2), C(O)O(R2), C(O)N(R2)(R3), C(═N(R3))(R2), C(═N(OR3))(R2), S(R2), S(O)(R2), S(O 2 )(R2) and S(O 2 )N(R2)(R3), in which each R2, R3 and R4 is independently selected from the group consisting of hydrogen, alkyl, aryl, cycloalkyl, substituted alkyl, substituted aryl, substituted cycloalkyl, alkenyl and substituted alkenyl;

l) X is selected from the group consisting of S(O 2 )—NH; S(O 2 )—O; NH—S(O 2 ); and O—S(O 2 );

m) Z is selected from the group consisting of alkyl, alkenyl, aryl, cycloalkyl, substituted alkyl, substituted alkenyl, substituted aryl, and substituted cycloalkyl;

n) R is chosen from hydrogen or C1-C3 alkyl; or

an enantiomer, stereoisomer, rotomer or a tautomer thereof, or a pharmaceutically acceptable salt, solvate or a derivative thereof.

27. The method as set forth in claim 26 , wherein the kinase is FAK.

28. The method as set forth in claim 26 , wherein the kinase is Aurora2.

29. The method as set forth in claim 26 , wherein the kinase is KDR.

30. The method as set forth in claim 26 , wherein the kinase is selected from the group consisting of Src, Tie2, IGF1R, CDK2 and CDK4.

31. The method as set forth in claim 30 , wherein the kinase is selected from the group consisting of Src and Tie2.

32. The method as set forth in claim 26 , wherein the cancer is breast cancer.